Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
PD Dr. Grégoire Wuerzner
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01734096CT.gov Renal Response to Lower Body Negative Pressure in Pre-hypertensive States | — | Completed | — | — | — |
NCT02166697CT.gov Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome" | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertensive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Candesartan Cilexetil (this asset) | PD Dr. Grégoire Wuerzner | Approved | BB · 65 |
| Valsartan | University of Alabama at Birmingham | P4 | BBB |
| Hydrochlorothiazide | University of Kansas Medical Center | P4 | BBB |
| Amlodipine | Jing Liu | P4 | BBB |
| Losartan | Rong Zhang | P4 | BBB |
| Trandolapril | University of Florida | P4 | BBB |
| Olmesartan Medoxomil | Virginia Polytechnic Institute and State University | P4 | BBB |
| Corpril | University of Michigan | P4 | BBB |
| Cilnidipine | Boryung Pharmaceutical Co., Ltd | P4 | BBB |
+42 more in the Hypertensive Disorder cohort
Other indications for Candesartan Cilexetil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Resistant Hypertension | — | P4 | BB · 69 |
| Obesity Disorder | — | P4 | B · 56 |
| Stroke Disorder | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Candesartan Cilexetil in Hypertensive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/candesartan-cilexetil-hypertensive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →